NDAINJECTIONSOLUTION
Approved
Sep 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
2
Mechanism of Action
double-stranded siRNA, conjugated to GalNAc aminosugar residues. After subcutaneous administration, the GalNAc-conjugated sugars bind to asialoglycoprotein receptors (ASGPR) to deliver nedosiran to hepatocytes. Nedosiran reduces levels of hepatic lactate dehydrogenase (LDH) via the degradation of…
Clinical Trials (2)
Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function
Started Feb 2022
27 enrolled
Primary HyperoxaluriaPrimary Hyperoxaluria Type 1Primary Hyperoxaluria Type 2+1 more
Treatment of Primary Hyperoxaluria Type 1 With Nedosiran
Primary Hyperoxaluria Type 1 (PH1)
Loss of Exclusivity
LOE Date
Oct 12, 2038
153 months away
Patent Expiry
Oct 12, 2038
Exclusivity Expiry
Sep 29, 2030